再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 06-12 16:00:00 EDT

612.14

+0.66

+0.11%

盘后616.09

+3.95+0.65%

19:52 EDT

最高616.55	最低605.01	成交量71.78万
今开613.11	昨收611.48	日振幅1.89%
总市值647.15亿	流通市值632.36亿	总股本1.06亿
成交额4.40亿	换手率0.69%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":612.14,"timestamp":1781294400000,"preClose":611.48,"halted":0,"volume":717780,"hourTrading":{"tag":"盘后","latestPrice":616.09,"preClose":612.14,"latestTime":"19:52 EDT","volume":14125,"amount":8647109.78,"timestamp":1781308378577,"change":3.95,"changeRate":0.006453,"amplitude":0.006453},"delay":0,"changeRate":0.001079348466016825,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"休市中","change":0.66,"latestTime":"06-12 16:00:00 EDT","open":613.11,"high":616.545,"low":605.01,"amount":439994230.3848,"amplitude":0.018864,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":611.48,"dividendRate":0.005894,"preHourTrading":{"tag":"盘前","latestPrice":611.51,"preClose":611.48,"latestTime":"09:29 EDT","volume":300,"amount":183961.83,"timestamp":1781270957134,"change":0.03,"changeRate":0.000049,"amplitude":0.02772},"postHourTrading":{"tag":"盘后","latestPrice":616.09,"preClose":612.14,"latestTime":"19:52 EDT","volume":14125,"amount":8647109.78,"timestamp":1781308378577,"change":3.95,"changeRate":0.006453,"amplitude":0.006453},"volumeRatio":0.6921738585856624,"impliedVol":0.3191,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1104752887","title":"异动解读｜再生元制药公司盘中下跌3.07%，三期临床失败叠加Eylea生物类似药申请重压","url":"https://stock-news.laohu8.com/highlight/detail?id=1104752887","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104752887?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:29","pubTimestamp":1780936189,"startTime":"0","endTime":"0","summary":"6月8日，再生元制药公司盘中下跌3.07%，报615.91美元/股，成交额1.57亿美元。消息面上，多重利空共振施压股价。此外，冰岛生物制药公司Alvotech联合Teva再次向FDA提交针对再生元核心产品Eylea的生物类似药上市申请，进一步加剧市场对其眼科业务收入遭受侵蚀的担忧。同日生物科技板块整体承压，艾伯维跌2.35%、吉利德跌1.41%、安进跌1.18%，行业情绪偏弱加大下行压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128409346","title":"Parabilis Medicines拟将约1.5亿美元IPO收益用于继续推进Zolucatetide治疗硬纤维瘤的临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1128409346","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128409346?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:21","pubTimestamp":1780568476,"startTime":"0","endTime":"0","summary":"Parabilis Medicines公司计划，将首次公开募股所筹资金中的约1.5亿美元，用于持续推动其候选药物Zolucatetide在硬纤维瘤领域的临床开发进程。此举旨在加速该疗法的研发，以应对这一临床需求未满足的疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","BK4585","LU0320765992.SGD","LU0289739699.SGD","LU0889565916.HKD","BK4139","LU2089984988.USD","LU2362541513.USD","LU0823416689.USD","LU2468319806.SGD","LU1974910355.USD","LU0823434740.USD","LU0058720904.USD","LU2362540622.SGD","BK4588","LU0053666078.USD","LU0823434583.USD","LU1917777945.USD","LU2023250504.SGD","LU0882574055.USD","LU2362541273.HKD","LU2106854487.HKD","LU0109394709.USD","REGN","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111077391","title":"Parabilis Medicines宣布与再生元制药达成协议，后者将斥资约7500万美元在同步私募中认购其普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1111077391","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111077391?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:20","pubTimestamp":1780568423,"startTime":"0","endTime":"0","summary":"再生元制药公司已同意在一项同步进行的私募融资中，以约7500万美元的价格购入Parabilis Medicines Inc的普通股。此项交易标志着两家生物技术公司在资本层面的重要合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2362540622.SGD","LU0882574055.USD","LU2468319806.SGD","LU1974910355.USD","LU1917777945.USD","LU0823434740.USD","LU2023250504.SGD","LU0320765992.SGD","REGN","LU0823434583.USD","LU2237438978.USD","BK4588","LU2106854487.HKD","LU2089984988.USD","LU0058720904.USD","BK4139","LU2362541273.HKD","LU2362541513.USD","BK4585","LU0053666078.USD","LU0889565916.HKD","LU0114720955.EUR","LU0823416689.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157154735","title":"异动解读｜再生元制药公司盘中上涨3.07%，埃博拉抗体获世卫组织推荐叠加合作扩展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1157154735","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157154735?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:35","pubTimestamp":1780504537,"startTime":"0","endTime":"0","summary":"6月3日，再生元制药公司盘中上涨3.07%，报621.42美元/股，成交额2.1亿美元。消息面上，多重利好共振推动股价走强。一方面，世界卫生组织推荐再生元研发的单克隆抗体Maftivimab用于应对当前本迪布焦型埃博拉病毒疫情，体外实验数据显示该药物对包括邦迪布焦病毒在内的多种埃博拉病毒株具有广泛抗病毒活性，为公司管线增添公共卫生应急价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133955723","title":"CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133955723","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133955723?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488342,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX与再生元制药公司之间的合作迎来了重大扩展。根据最新协议，再生元已获得针对6个额外靶点的选择权，此举有望将双方的合作范围进一步拓宽。协议条款显示，再生元制药公司为获得这些新靶点的选择权，已向CytomX支付了一笔预付款。若将现有合作中的潜在付款与此次新增的里程碑款项相结合，CytomX从这项合作中可能获得的总里程碑付款最高可达约40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2089984988.USD","LU2362541513.USD","LU1917777945.USD","REGN","BK4139","LU2023250504.SGD","LU0053666078.USD","LU0882574055.USD","LU2362540622.SGD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU0823434583.USD","LU0823434740.USD","LU2237438978.USD","LU0320765992.SGD","LU2468319806.SGD","BK4585","CTMX","LU2362541273.HKD","LU0289739699.SGD","LU1974910355.USD","LU0058720904.USD","LU0889565916.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194253037","title":"再生元制药公司：Maftivimab在体外对包括邦迪布焦在内的多种埃博拉病毒株展现广泛活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1194253037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194253037?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998475,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的研究数据显示，其单克隆抗体疗法Maftivimab在体外实验中，对包括邦迪布焦病毒在内的多种埃博拉病毒物种均表现出广泛的抗病毒活性。这一发现为该疗法的潜在应用范围提供了新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU2237438978.USD","REGN","LU0053666078.USD","LU0823434740.USD","LU2089984988.USD","LU2362541273.HKD","LU2106854487.HKD","LU2023250504.SGD","LU0823434583.USD","BK4588","LU0109394709.USD","LU2468319806.SGD","LU0114720955.EUR","LU1974910355.USD","LU2362540622.SGD","LU2362541513.USD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","BK4139","LU1917777945.USD","LU0889565916.HKD","LU0823416689.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148240042","title":"再生元制药：Maftivimab获推荐作为单药疗法在当前疫情中展开研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148240042","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148240042?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998471,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其单克隆抗体药物Maftivimab已获建议，在当前爆发的疫情中作为单药疗法进行深入研究。这一推荐基于对该药物潜在疗效的初步评估，旨在探索其在独立使用时的安全性与有效性，为应对公共卫生挑战提供新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0823434583.USD","BK4139","LU0114720955.EUR","LU2362541273.HKD","LU0109394709.USD","LU0823416689.USD","LU2468319806.SGD","LU1917777945.USD","LU2237438978.USD","LU0053666078.USD","LU2023250504.SGD","LU2089984988.USD","LU0882574055.USD","LU2362540622.SGD","LU1974910355.USD","LU0889565916.HKD","REGN","LU0058720904.USD","LU0289739699.SGD","LU0823434740.USD","BK4585","BK4588","LU2106854487.HKD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148009972","title":"再生元埃博拉抗体获世卫组织推荐，用于应对当前本迪布焦型埃博拉病毒疫情","url":"https://stock-news.laohu8.com/highlight/detail?id=1148009972","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148009972?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:00","pubTimestamp":1779998412,"startTime":"0","endTime":"0","summary":"世界卫生组织已推荐将再生元制药公司研发的埃博拉抗体，用于应对当前爆发的本迪布焦型埃博拉病毒疫情，并建议在调查性框架下使用。这一建议旨在为应对此次疫情提供一种潜在的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","REGN","LU0109394709.USD","LU0053666078.USD","BK4139","LU2362540622.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2362541513.USD","LU2089984988.USD","LU0823434740.USD","LU2106854487.HKD","BK4585","BK4588","LU2023250504.SGD","LU0114720955.EUR","LU0823434583.USD","LU1917777945.USD","LU2468319806.SGD","LU0320765992.SGD","LU1974910355.USD","LU0823416689.USD","LU0058720904.USD","LU2237438978.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134477169","title":"异动解读｜再生元制药盘中上涨3.25%，报648.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134477169","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134477169?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:54","pubTimestamp":1779285285,"startTime":"0","endTime":"0","summary":"5月20日，再生元制药盘中上涨3.25%，报648.97美元/股，成交额5288.26万美元。再生元制药所在的生物科技行业中，个股中，安进跌0.05%，Immunovant, Inc.涨25.03%，Silexion Therapeutics Corp涨112.27%，Roivant Sciences Ltd.涨11.8%，ImmunityBio, Inc.涨6.19%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164541553","title":"再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1164541553","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164541553?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:00","pubTimestamp":1779224413,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，再生元制药公司已同意通过一项并行私募交易，购买其价值约7500万美元的普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0320765992.SGD","REGN","LU0053666078.USD","LU2362541273.HKD","LU0823416689.USD","BK4588","LU2237438978.USD","LU0889565916.HKD","LU0109394709.USD","LU0114720955.EUR","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","BK4585","LU0058720904.USD","LU0882574055.USD","LU2362541513.USD","LU2468319806.SGD","BK4139","LU0823434740.USD","LU2089984988.USD","LU0823434583.USD","LU0289739699.SGD","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142060213","title":"再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1142060213","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142060213?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102112,"startTime":"0","endTime":"0","summary":"再生元制药公司披露，最新达成的协议条款中，除了已公布的核心内容外，还包含了价值约22亿美元的额外潜在里程碑付款。\n此外，协议还设定了分级结构的特许权使用费安排，该安排将根据未来产品的商业化表现或特定销售目标的达成情况而动态调整。\n这些财务条款的加入，显著提升了此次交易的整体潜在价值，并体现了合作方对相关研发项目商业化前景的共同信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0823434583.USD","BK4139","LU0114720955.EUR","LU2362541273.HKD","LU0109394709.USD","LU0823416689.USD","LU2468319806.SGD","LU1917777945.USD","LU2237438978.USD","LU0053666078.USD","LU2023250504.SGD","LU2089984988.USD","LU0882574055.USD","LU2362540622.SGD","LU1974910355.USD","LU0889565916.HKD","REGN","LU0058720904.USD","LU0289739699.SGD","LU0823434740.USD","BK4585","BK4588","LU2106854487.HKD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167587402","title":"再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167587402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167587402?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102110,"startTime":"0","endTime":"0","summary":"根据协议条款，若公司支付额外的期权付款，再生元制药公司可能启动针对更多靶点的研发项目。这一安排为该公司未来拓展研发管线提供了灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","BK4585","LU0823434583.USD","LU0109394709.USD","LU0058720904.USD","LU0823434740.USD","LU2362541513.USD","BK4588","LU0289739699.SGD","LU2089984988.USD","LU2468319806.SGD","LU0053666078.USD","LU2237438978.USD","REGN","LU0823416689.USD","BK4139","LU0889565916.HKD","LU2106854487.HKD","LU0882574055.USD","LU0114720955.EUR","LU1917777945.USD","LU1974910355.USD","LU0320765992.SGD","LU2362540622.SGD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190474575","title":"再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474575","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190474575?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:05","pubTimestamp":1779098717,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals, REGN）的评级遭遇下调。投资机构Leerink Partners将其对该公司的投资评级从“跑赢大盘”（Outperform）调降至“与大盘持平”（Market Perform）。与此同时，该机构大幅下调了再生元制药的目标股价，从原先的792美元削减至641美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4585","LU2089984988.USD","LU2362541513.USD","LU0289739699.SGD","BK4139","LU0058720904.USD","LU2106854487.HKD","LU0053666078.USD","LU2023250504.SGD","LU0882574055.USD","LU0823434583.USD","LU2362540622.SGD","LU0823416689.USD","LU0823434740.USD","LU2362541273.HKD","LU1917777945.USD","LU1974910355.USD","LU2237438978.USD","LU2468319806.SGD","REGN","BK4588","LU0889565916.HKD","LU0109394709.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114706209","title":"市场聚焦：道明尼资源、新纪元能源、联合健康","url":"https://stock-news.laohu8.com/highlight/detail?id=1114706209","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114706209?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:14","pubTimestamp":1779095680,"startTime":"0","endTime":"0","summary":"消息传出后，道明尼资源股价在盘前交易中飙升12%，而新纪元能源股价则小幅走低。据悉，这笔交易最快可能于今日达成。联合健康 ：这家健康保险巨头的股价在盘前下跌了5%，此前伯克希尔哈撒韦  在周五晚间披露已清仓其在该公司的股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","IE00BGHQF417.EUR","LU1066051811.HKD","IE00B3S45H60.SGD","LU2133065610.SGD","LU0154236417.USD","LU1551013342.USD","LU0149725797.USD","LU0057025933.USD","SG9999014880.SGD","LU2023250843.SGD","IE0009355771.USD","LU0689472784.USD","LU0354030438.USD","BK4550","LU0203347892.USD","LU2361044865.SGD","LU0124676726.USD","LU0310799852.SGD","LU0456855351.SGD","LU2244417387.USD","LU1035773651.USD","LU0289739343.SGD","LU1057294990.SGD","LU0109394709.USD","BK4588","LU2168564065.EUR","LU2089984988.USD","LU1153585028.USD","SGXZ99366536.SGD","IE00B19Z9P08.USD","LU0912757837.SGD","LU0256863811.USD","LU0211328371.USD","LU1066051225.USD","LU1280957306.USD","LU2237438978.USD","LU0320765059.SGD","LU2362541513.USD","LU0976567544.SGD","LU2347655073.USD","LU0823414551.USD","IE00BD4GTW91.USD","BK4139","BK4176","LU2362541273.HKD","LU0742534661.SGD","LU0689626769.HKD","LU2275660780.HKD","HK0000914660.USD","LU0158827948.USD","LU0234570918.USD","IE00BZ9MQY76.HKD","IE00BLSP4239.USD","LU2360032135.SGD","LU1084165304.USD","LU0048584097.USD","LU0320765646.SGD","LU1778281490.HKD","IE00BMG7P926.USD","LU1061106388.HKD","LU1934455863.HKD","LU0861579265.USD","LU1291159041.SGD","LU1929549753.HKD","LU2106854487.HKD","LU1119994496.HKD","LU2087625088.SGD","BK4597","LU0107464264.USD","DAL","LU0312595415.SGD","IE00B19Z9505.USD","SG9999001176.SGD","IE00BD4GTV84.USD","LU0553294199.USD","REGN","BK4606","LU0251142724.SGD","LU0787776722.HKD","IE00BMG7P702.HKD","LU2506951792.HKD","LU1854104046.USD","SG9999014914.USD","IE00BJJMRY28.SGD","SG9999018857.SGD","LU1670628061.USD","LU2462611646.USD","IE00BFSS7M15.SGD","IE00B19Z3B42.SGD","LU0823414478.USD","LU0511384066.AUD","LU0130102774.USD","IE00BWXC8680.SGD","UNHG","LU1621768206.USD","LU0965509283.SGD","LU2357125470.USD","LU0234572021.USD","LU1064131342.USD","IE00BD4GTT62.SGD","LU1037948541.HKD","LU2236285917.USD","SGXZ31699556.SGD","BK4581","BK4585","SGXZ51526630.SGD","LU2298064838.USD","LU0048573561.USD","LU1791710582.SGD","LU0342679015.USD","LU0211327993.USD","LU2125154778.USD","IE00BK4W5M84.HKD","LU0496365809.HKD","SG9999013999.USD","LU0058720904.USD","LU0128525929.USD","LU0648000940.SGD","IE0004445015.USD","IE00B1XK9C88.USD","IE00BJTD4V19.USD","IE00B3CCJ633.GBP","IE00B2B36J28.USD","LU2211815571.USD","LU0029864427.USD","UNHW","M","LU1093756325.SGD","LU1261432733.SGD","LU1267930730.SGD","LU2168564149.EUR","IE00BMG7P587.USD","LU2324357040.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0310800965.SGD","RYAAY","LU0266013472.USD","LU2023250504.SGD","LU2361044949.HKD","IE00B19Z8W00.USD","LU1093756168.USD","D","LU0417517546.SGD","LU1363072403.SGD","IE0004445239.USD","LU2279689827.SGD","LU0198837287.USD","LU1988902786.USD","LU2637428348.USD","LU1069347547.HKD","LU1814569148.SGD","BK4220","LU1003077747.HKD","LU0211326839.USD","LU2362540622.SGD","LU0077335932.USD","BRKC","LU2491049909.HKD","LU1989771016.USD","LU2168563687.JPY","IE00B894F039.SGD","LU1712237335.SGD","IE00B775H168.HKD","LU1548497426.USD","LU1621767737.EUR","LU0661504455.SGD","IE00BN29S564.USD","LU0211326755.USD","IE00BBT3K403.USD","HK0000914686.HKD","LU1066051498.USD","LU0882574055.USD","UNH","LU0320765992.SGD","LU1978683503.SGD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","LU1074936037.SGD","LU0289739699.SGD","IE0005OL40V9.USD","LU0122379950.USD","IE00B29SXK94.USD","LU1551013425.SGD","LU1201861165.SGD","LU1674673691.USD","BK4533","LU1506573853.SGD","IE00BFMHRM44.USD","LU0820561818.USD","LU0823434740.USD","SGXZ81514606.USD","LU2108987350.USD","IE000M9KFDE8.USD","LU1267930227.SGD","LU0726765562.USD","LU2211814178.USD","SG9999002232.USD","LU0157215616.USD","BK4534","LU0708995401.HKD","LU0238689110.USD","LU1732800096.USD","SG9999001176.USD","IE00BKDWB100.SGD","LU1623119135.USD","BK4208","LU1917777945.USD","LU1914381329.SGD","LU0345770993.USD","LU0889565916.HKD","LU0353189763.USD","IE00BMG7P819.SGD","LU0943347566.SGD","BK4500","LU2089284900.SGD","LU0097036916.USD","LU1791710400.SGD","LU2023251221.USD","LU2264538146.SGD","LU0011850046.USD","LU0289960550.SGD","IE00BFTCPJ56.SGD","BRKD","LU2491050154.USD","LU0432979614.USD","IE00BFSS8Q28.SGD","BRK.B","LU0823434583.USD","LU1983299246.USD","SG9999002224.SGD","LU0820561909.HKD","IE00B3T34201.USD","LU0128525689.USD","LU1621767810.EUR","BRKW","IE00B4R5TH58.HKD","LU1267930573.SGD","LU2468319806.SGD","LU0820562030.AUD","LU0965509101.SGD","LU2298322129.HKD","LU1854103824.USD","LU2294711713.HKD","LU0965508806.USD","IE00BKPKM429.USD","IE00BJT1NW94.SGD","LU0310800379.SGD","LU2498475776.HKD","LU1670627923.USD","LU0971096721.USD","LU0353189680.USD","LU0210528500.USD","LU1366192091.USD","IE00BSNM7G36.USD","LU1267930490.SGD","LU0079474960.USD","BK4154","LU0786609619.USD","LU0124384867.USD","LU0528227936.USD","LU2500361329.USD","BK4532","IE00B4JS1V06.HKD","BK4566","IE00BK4W5L77.USD","IE00BMG7P694.USD","LU2552382058.USD","LU0109391861.USD","LU0980610538.SGD","LU0130103400.USD","IE00B1BXHZ80.USD","LU0557290698.USD","LU2552382215.SGD","BRKU","LU1939255532.USD","BK4081","LU0354030511.USD","LU1023059063.AUD","LU0949170772.SGD","IE00B775SV38.USD","LU2089283258.USD","LU0708994859.HKD","IE00BJLML261.HKD","IE00B19Z8X17.USD","NEE","IE00BZ18W340.USD","LU1201861249.SGD","LU1974910355.USD","LU1621768115.EUR","LU0640476718.USD","LU0203345920.USD","LU2357305700.SGD","IE0002270589.USD","LU1571399168.USD","LU0672654240.SGD","LU2112291526.USD","LU1496350502.SGD","IE00BN8TJ469.HKD","SG9999017495.SGD","LU0114720955.EUR","LU0302445910.USD","LU2487616109.SGD","IE00B29SXL02.USD","LU1934455194.USD","LU2361045086.USD","IE00BJTD4N35.SGD","IE00BLSP4452.SGD","LU0683600562.USD","IE00B19Z3581.USD","LU0316494557.USD","SG9999018865.SGD","BK4548","LU2048586759.USD","LU0965509010.AUD","SG9999014906.USD","LU1720051108.HKD","LU2238339852.HKD","IE00BZ1G4Q59.USD","LU0175139822.USD","LU0006061336.USD","IE00B7KXQ091.USD","LU1934455277.USD","LU0094547139.USD","LU0738911758.USD","SG9999014898.SGD","LU0187121727.USD","LU0545039389.USD","LU0795875169.SGD","LU2168564495.EUR","LU0251132253.USD","IE00BZ18W456.USD","LU2491050071.SGD","LU0648001328.SGD","LU0724618433.USD","LU1674673428.USD","IE00BFXG1179.USD","LU2249611893.SGD","LU2242649171.HKD","IE00BKVL7J92.USD","LU0289961442.SGD","LU2461242641.AUD","LU1323610961.USD","LU1883866441.USD","LU2384288077.EUR","LU1037948897.HKD","LU0069063385.USD","IE0034235303.USD","LU0795875086.SGD","LU0251131958.USD","LU0052756011.USD","LU0823416689.USD","LU1366333091.USD","LU0345770308.USD","IE0002141913.USD","LU0158827781.USD","LU2168564222.USD","LU2028103732.USD","LU0053666078.USD","IE00BJJMRZ35.SGD","LU1718418525.SGD","IE00B2PGVK34.USD","BK4103","LU1732799900.SGD","LU1720051017.SGD","LU2111349929.HKD","IE00BJJMRX11.SGD","LU1162221912.USD","LU0472753341.HKD","LU2552382132.HKD","LU2125154935.USD","LU2271345857.HKD","IE00BMQBXF63.USD","BK4008","LU2394011477.USD","LU2347655156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026825","title":"再生元制药(REGN)盘前大跌11% 核心药物Ⅲ期试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026825","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026825?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:53","pubTimestamp":1779094391,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元制药（REGN）盘前股价大幅下挫，下跌11.2%，报 619.97 美元。消息面上，。5 月 15 日，再生元制药宣布，其核心药物 fianlimab 联合西米普利单抗的 Ⅲ 期试验未达到主要终点。数据显示，高剂量联合治疗组中位无进展生存期为 11.5 个月，优于对照组的 6.4 个月，但试验 P 值为 0.0627，未达到统计学显著性要求，意味着疗效优势或为偶然结果。此次试验失利直接影响市场对该公司肿瘤领域竞争力的信心。尽管再生元制药将希望寄托于另一项与百时美施贵宝已获批疗法头对头的试验，但此次失败带来的不确定性，仍对其股价造成显著冲击，短期市场信心受挫。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300532","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","REGN","LU0109394709.USD","LU0053666078.USD","BK4139","LU2362540622.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2362541513.USD","LU2089984988.USD","BK1574","LU0823434740.USD","LU2106854487.HKD","BK4585","BK4588","LU2023250504.SGD","LU0114720955.EUR","LU0823434583.USD","LU1917777945.USD","LU2468319806.SGD","LU0320765992.SGD","01477","BK1191","LU1974910355.USD","LU0823416689.USD","LU0058720904.USD","LU2237438978.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154313869","title":"再生元制药公司股价盘前重挫11.2%，因晚期黑色素瘤药物研究未达统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1154313869","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154313869?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:31","pubTimestamp":1779093075,"startTime":"0","endTime":"0","summary":"再生元制药公司股价在盘前交易中遭遇重挫，跌幅达11.2%。这一急剧下跌源于该公司一项备受关注的晚期黑色素瘤药物研究未能达到预设的主要终点，即未能在统计学上显示出显著的有效性。\n该消息对市场信心造成显著打击，凸显了新药研发在关键临床阶段所面临的高风险与不确定性。投资者迅速对此负面数据做出反应，导致股价大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0823434583.USD","LU2023250504.SGD","LU2106854487.HKD","LU0823416689.USD","LU0289739699.SGD","LU2362541273.HKD","LU2362541513.USD","LU0823434740.USD","LU2089984988.USD","LU0889565916.HKD","LU1917777945.USD","BK4139","LU2468319806.SGD","LU2237438978.USD","LU2362540622.SGD","LU0114720955.EUR","LU0320765992.SGD","LU0053666078.USD","LU0109394709.USD","BK4585","LU0882574055.USD","LU1974910355.USD","REGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149676722","title":"再生元制药关键试验未达主要终点：无进展生存期改善未具统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149676722","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149676722?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:23","pubTimestamp":1778890989,"startTime":"0","endTime":"0","summary":"再生元制药公司一项临床试验的主要终点——无进展生存期的改善——未能达到统计学显著性标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU2468319806.SGD","LU1974910355.USD","LU2106854487.HKD","LU0823434740.USD","LU2362540622.SGD","REGN","LU0882574055.USD","LU0289739699.SGD","LU2362541513.USD","LU0823434583.USD","BK4588","LU0889565916.HKD","BK4139","LU2237438978.USD","LU2089984988.USD","LU1917777945.USD","LU0114720955.EUR","LU2362541273.HKD","LU0109394709.USD","LU0320765992.SGD","BK4585","LU0823416689.USD","LU2023250504.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122731183","title":"再生元制药公布一线治疗不可切除或转移性黑色素瘤的Fianlimab（Lag-3抑制剂）联合疗法三期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1122731183","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122731183?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:20","pubTimestamp":1778890817,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals）就其研发的Fianlimab（一种Lag-3抑制剂）联合疗法，在一线治疗不可切除或转移性黑色素瘤患者中的三期临床试验提供了最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0889565916.HKD","LU2362541513.USD","LU0823434583.USD","BK4139","LU0109394709.USD","LU2106854487.HKD","REGN","LU2237438978.USD","BK4588","BK4585","LU2089984988.USD","LU0882574055.USD","LU0320765992.SGD","LU2362540622.SGD","LU1917777945.USD","LU0289739699.SGD","LU0823434740.USD","LU2023250504.SGD","LU0053666078.USD","LU0114720955.EUR","LU1974910355.USD","LU2362541273.HKD","LU2468319806.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149675812","title":"再生元制药REMODEL试验安全性结果与已知度普利尤单抗特征一致；不良事件发生率62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149675812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149675812?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:10","pubTimestamp":1777979450,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其REMODEL临床试验的安全性数据与度普利尤单抗已知的安全性特征相符。试验结果显示，接受度普利尤单抗治疗的患者中不良事件发生率为62%。\n这一数据进一步验证了该药物在临床使用中的安全性表现，为后续临床应用提供了重要参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2362541273.HKD","REGN","LU1974910355.USD","LU0882574055.USD","LU2468319806.SGD","LU2362540622.SGD","BK4588","LU2023250504.SGD","LU0823416689.USD","LU0109394709.USD","LU0289739699.SGD","LU2362541513.USD","LU0823434583.USD","LU0053666078.USD","LU1917777945.USD","LU0058720904.USD","LU0823434740.USD","BK4139","LU2237438978.USD","BK4585","LU2089984988.USD","LU0889565916.HKD","LU2106854487.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166184363","title":"再生元制药Dupixent治疗24周实现食管扩张性较基线改善9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166184363","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166184363?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979234,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其与赛诺菲联合开发的Dupixent在临床试验中取得突破性进展。数据显示，治疗24周后，患者食管扩张性指标较基线水平显著提升9%。\n该结果来自针对嗜酸性粒细胞性食管炎患者的III期研究。食管扩张性改善意味着患者吞咽功能得到实质性恢复，这对长期受进食困难困扰的患者具有重要临床意义。\nDupixent作为全人源单克隆抗体，通过抑制IL-4和IL-13信号通路发挥治疗作用。此次研究还观察到患者组织学异常和症状评分均获得显著改善。\n这项突破为嗜酸性粒细胞性食管炎患者提供了新的治疗选择。目前该适应症尚未获得监管批准，相关数据将作为申报材料提交给药品监管机构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0058720904.USD","BK4139","LU0823416689.USD","LU0109394709.USD","LU2237438978.USD","LU2468319806.SGD","LU2362541273.HKD","REGN","LU0823434740.USD","LU0889565916.HKD","LU1974910355.USD","LU1917777945.USD","LU0882574055.USD","BK4588","LU0823434583.USD","LU2106854487.HKD","LU0053666078.USD","LU2362541513.USD","LU2089984988.USD","LU0114720955.EUR","LU0289739699.SGD","LU2023250504.SGD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0367},{"period":"1month","weight":-0.1497},{"period":"3month","weight":-0.1792},{"period":"6month","weight":-0.1742},{"period":"1year","weight":0.173},{"period":"ytd","weight":-0.2069}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.416667,"avgChangeRate":0.006438},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}